Efficacy and Safety of Immune Checkpoint Inhibitors in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma: A Systematic Review and Meta-Analysis

0
0
0

Efficacy and Safety of Immune Checkpoint Inhibitors in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma: A Systematic Review and Meta-Analysis

Introduction

Nasopharyngeal carcinoma (NPC) is a rare malignancy with a distinct geographical distribution, showing high prevalence in southern China and Southeast Asia. Epstein-Barr virus (EBV) infection is a well-established etiological factor, contributing to its unique tumor microenvironment characterized by dense immune cell infiltration. While intensity-modulated radiotherapy remains the cornerstone for locoregional disease, recurrent or metastatic NPC (RM-NPC) relies on systemic therapies to improve survival outcomes. Historically, gemcitabine combined with cisplatin or carboplatin (GP) has been the standard first-line regimen, offering a median overall survival (OS) of approximately 22–30 months. However, the prognosis for RM-NPC remains suboptimal, necessitating novel therapeutic strategies.

The immunogenic nature of EBV-associated NPC has spurred interest in immune checkpoint inhibitors (ICIs). Early-phase trials demonstrated promising activity of PD-1/PD-L1 inhibitors in later-line settings, with objective response rates (ORR) ranging from 20% to 40%. However, randomized trials comparing ICIs with chemotherapy in second-line settings failed to show significant survival benefits. Recent landmark studies—CAPTAIN-1st, JUPITER-02, and RATIONALE 309—established the superiority of combining ICIs with chemotherapy (ICI + Chemo) over chemotherapy alone in first-line RM-NPC, leading to its inclusion in clinical guidelines. Despite these advances, unanswered questions persist regarding predictive biomarkers, comparative efficacy in non-endemic populations, and the role of ICIs in subsequent-line therapies.

Methods

A systematic search of PubMed, Embase, Cochrane Library, and conference proceedings (ASCO, ESMO, AACR, WCLC) identified 15 trials (3 first-line randomized controlled trials [RCTs], 12 later-line studies) involving 1,928 patients. Inclusion criteria focused on RCTs or prospective studies evaluating ICIs in RM-NPC. Data extraction covered progression-free survival (PFS), OS, ORR, disease control rate (DCR), and adverse events (AEs). Risk of bias was assessed using Cochrane Collaboration tools for RCTs and MINORS criteria for single-arm studies.

Statistical analyses compared hazard ratios (HRs) for survival outcomes and risk ratios (RRs) for dichotomous endpoints. Heterogeneity was quantified using I² statistics, with random-effects models applied for significant heterogeneity (I² >50%). Subgroup analyses explored clinical factors (age, sex, ECOG PS, PD-L1 expression) and treatment settings. Sensitivity analyses ensured robustness, and publication bias was evaluated via funnel plots.

Results

First-Line ICI + Chemo vs. Chemotherapy

Pooled data from three RCTs (n = 716) demonstrated significant improvements with ICI + Chemo:

  • PFS: Median PFS was 14.05 months (95% CI: 13.07–15.03) vs. 7.20 months (95% CI: 6.67–7.73) for chemotherapy alone (HR = 0.52, 95% CI: 0.43–0.63; P <0.001).
  • ORR: 79% (95% CI: 74–82%) vs. 68% (95% CI: 63–72%; RR = 1.14, P = 0.001).
  • Safety: Grade 3–5 AEs occurred in 88% (ICI + Chemo) vs. 87% (chemotherapy), with no significant differences in treatment discontinuation (RR = 1.63, P = 0.090) or fatal AEs (RR = 1.75, P = 0.311). Immune-related AEs (irAEs) of any grade occurred in 59% of ICI + Chemo patients, but only 8% were grade ≥3.

Subgroup analyses confirmed consistent PFS benefits across all subgroups, including age, ECOG PS, histology (keratinizing vs. non-keratinizing), and PD-L1 expression levels. Notably, PD-L1 expression (using cutoffs of 1% or 10%) did not predict efficacy (P = 0.553 for interaction).

Subsequent-Line ICIs as Monotherapy

Twelve studies (n = 1,212) evaluated ICIs in later-line settings:

  • Efficacy: Pooled ORR was 24% (95% CI: 20–28%), DCR 52% (95% CI: 45–59%), and median PFS 4.12 months (95% CI: 2.93–5.31). Heterogeneity was significant (I² = 83% for PFS), reflecting variability in patient populations and ICI agents.
  • Safety: Grade 1–5 AEs occurred in 79% (95% CI: 71–88%), with 14% grade ≥3. Serious AEs and treatment discontinuations were reported in 12% and 2%, respectively.

Two RCTs directly compared ICIs with chemotherapy in second-line settings:

  • PFS: Chemotherapy outperformed ICIs (HR = 1.31, 95% CI: 1.01–1.68; P = 0.040), with median PFS of 5.88 months vs. 4.12 months.
  • ORR: No significant difference (24% vs. 26%; RR = 0.69, P = 0.250).

Discussion

First-Line ICI + Chemo: A New Standard

The meta-analysis solidifies ICI + Chemo as the first-line standard for RM-NPC, showing a 48% reduction in progression risk and a 14% absolute increase in ORR over chemotherapy. The consistent benefit across subgroups—irrespective of PD-L1 status, EBV DNA levels, or histology—suggests broad applicability, even in non-endemic regions with keratinizing subtypes. However, the modest ORR improvement highlights chemotherapy’s indispensable role, underscoring the need for strategies to enhance immunotherapeutic efficacy, such as dual checkpoint inhibition or novel combinations.

Biomarker Challenges

The lack of correlation between PD-L1 expression and outcomes contrasts with other cancers, possibly due to EBV-driven PD-L1 upregulation via latent membrane protein 1 (LMP1). This finding emphasizes the need for NPC-specific biomarkers, such as EBV DNA dynamics, tumor-infiltrating lymphocyte profiles, or genomic alterations (e.g., 11q13 amplifications).

Later-Line ICIs: Limited Efficacy

ICIs as monotherapy in pretreated patients showed modest activity, failing to surpass chemotherapy in RCTs. The pooled ORR of 24% and median PFS of 4.1 months reflect primary resistance in a subset of patients. Future studies should explore combinatorial approaches (e.g., ICIs with anti-angiogenics or CTLA-4 inhibitors) and biomarkers to identify responders.

Safety Considerations

The comparable AE profiles of ICI + Chemo and chemotherapy alone challenge the notion that immunotherapy inherently increases toxicity. Chemotherapy may mitigate irAE severity by modulating the immune microenvironment. In later-line settings, ICIs exhibited favorable safety, with grade ≥3 AEs occurring in only 14% of patients.

Limitations and Future Directions

The predominance of endemic populations in first-line trials limits generalizability. Mature OS data are awaited to confirm long-term benefits. Additionally, the heterogeneity in later-line studies complicates cross-trial comparisons. Prospective trials evaluating ICIs in non-endemic populations, predictive biomarkers, and novel combinations are warranted.

Conclusion

This meta-analysis establishes ICI + Chemo as a transformative first-line regimen for RM-NPC, offering significant PFS and ORR benefits without exacerbating toxicity. PD-L1 expression does not predict therapeutic response, necessitating biomarker discovery efforts. In later-line settings, ICIs alone demonstrate manageable safety but inferior efficacy to chemotherapy, highlighting the need for combinatorial strategies. These findings reinforce the importance of immunotherapy in NPC while delineating critical areas for future research.

doi.org/10.1097/CM9.0000000000003371

Was this helpful?

0 / 0